(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl} -pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor

European Journal of Pharmacology

Volumn 655, Issue 1-3, 2011, Pages 99-107

  Tajima, Atsushi ^a   Yamamoto, Koji ^a   Kozakai, Akinori ^a   Okumura Kitajima, Lisa ^a   Mita, Yasuo ^a   Kitano, Kiyokazu ^a   Jingu, Shigeji ^a   Nakaike, Shiro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

(Zucker fatty rat); Dipeptidyl peptidase IV; Glucagon like peptide 1 insulin; Impaired glucose tolerance; TS 021; Type 2 diabetes mellitus

Indexed keywords

4 FLUORO [[(2 HYDROXY 1,1 DIMETHYLETHYL)AMINO]ACETYL]PYRROLIDINE 2 CARBONITRILE MONOBENZENESULFONATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; TS 021; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAPLORHINI; HUMAN; HYPERGLYCEMIA; IC 50; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZENESULFONATES; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HAPLORHINI; HUMANS; INSULIN; MALE; PEPTIDE FRAGMENTS; PYRROLIDINES; RATS; SUBSTRATE SPECIFICITY;

EID: 79952538936     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.010     Document Type: Article

References (35)

1. B. Ahrén, H. Larsson, and J.J. Holst Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 82 1997 473 478 (Pubitemid 27068614)
2. B. Ahrén, J.J. Holst, H. Mårtensson, and B. Balkan Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice Eur J Pharmacol. 404 2000 239 245
3. B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson, M. Sandqvist, P. Båvenholm, S. Efendic, J.W. Eriksson, S. Dickinson, and D. Holmes Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diab. Care 25 2002 869 875 (Pubitemid 41094285)
4. B. Ahrén, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diab. Care 27 2004 2874 2880 (Pubitemid 39565052)
5. A. Baici, P. Salgam, K. Fehr, and A. Böni Inhibition of human elastase from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polysulfate (SP-54) Biochem. Pharmacol. 30 1981 703 708 (Pubitemid 11146817)
6. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, and X. Li Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 1999 1324 1331 (Pubitemid 29500969)
7. S. Bolen, L. Feldman, J. Vassy, L. Wilson, H.C. Yeh, S. Marinopoulos, C. Wiley, E. Selvin, R. Wilson, E.B. Bass, and F.L. Brancati Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann. Intern. Med. 147 2007 386 399 (Pubitemid 351664540)
8. I. Brandt, J. Joossens, X. Chen, M.B. Maes, S. Scharpé, I. De Meester, and A.M. Lambeir Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino] acetyl}-pyrrolidine-2-carbonitrile) Biochem. Pharmacol. 70 2005 134 143 (Pubitemid 40797877)
9. B.F. Burkey, P.K. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes, and J.E. Foley Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diab. Obes. Metab. 10 2008 1057 1061
10. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and J.W. Ensinck Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J. Clin. Invest. 93 1994 2263 2266 (Pubitemid 24143111)
11. C.F. Deacon, T.E. Hughes, and J.J. Holst Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 47 1998 764 769 (Pubitemid 28201806)
12. H. Fukushima, A. Hiratate, M. Takahashi, A. Mikami, M. Saito-Hori, E. Munetomo, K. Kitano, S. Chonan, H. Saito, A. Suzuki, Y. Takaoka, and K. Yamamoto Synthesis and structure-activity relationships of potent 4-fluoro-2- cyanopyrrolidine dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 16 2008 4093 4106 (Pubitemid 351484008)
13. C. Gilbert, D. Atlan, B. Blanc, and R. Portalier Proline iminopeptidase from Lactobacillus delbrueckii subsp. bulgaricus CNRZ 397: purification and characterization Microbiology 140 1994 537 542 (Pubitemid 24090622)
14. J.J. Holst Therapy of type 2 diabetes mellitus based on the actions of glucagonlike peptide-1 Diab. Metab. Res. Rev. 18 2002 430 441 (Pubitemid 36041598)
15. T.E. Hughes, M.D. Mone, M.E. Russell, S.C. Weldon, and E.B. Villhauer NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV Biochemistry 38 1999 11597 11603
16. M. Kirby, D.M. Yu, S. O'Connor, and M.D. Gorrell Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition Clin. Sci. (Lond.) 118 2010 31 41
17. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994 (Pubitemid 41401097)
18. H. Mitani, M. Takimoto, T.E. Hughes, and M. Kimura Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity Jpn J. Pharmacol. 88 2002 442 450 (Pubitemid 34516571)
19. H. Mitani, M. Takimoto, and M. Kimura Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity Jpn J. Pharmacol. 88 2002 451 458 (Pubitemid 34516572)
20. E. Naslund, B. Barkeling, N. King, M. Gutniak, J.E. Blundell, J.J. Holst, S. Rossner, and P.M. Hellstrom Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int. J. Obes. Relat. Metab. Disord. 23 1999 304 311 (Pubitemid 29118862)
21. S. Ogata, Y. Misumi, and Y. Ikehara Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain J. Biol. Chem. 264 1989 3596 3601 (Pubitemid 19063420)
22. R.P. Pauly, F. Rosche, M. Wermann, C.H. McIntosh, R.A. Pederson, and H.U. Demuth Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach J. Biol. Chem. 271 1996 23222 23229 (Pubitemid 26314761)
23. R.A. Pederson, H.A. White, D. Schlenzig, R.P. Pauly, C.H. McIntosh, and H.U. Demuth Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 1998 1253 1258 (Pubitemid 28357002)
24. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H. McIntosh, and R.A. Pederson Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 2002 943 950 (Pubitemid 34438335)
25. J.A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, F.C. Lynn, S. Piteau, H.U. Demuth, C.H. McIntosh, and R.A. Pederson Dipeptidyl peptidase IV inhibitor treatment stimulates L-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750 (Pubitemid 36323582)
26. R.E. Pratley, and A. Salsali Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes Curr. Med. Res. Opin. 23 2007 919 931 (Pubitemid 46631495)
27. R.L. Prigeon, S. Quddusi, B. Paty, and D.A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am. J. Physiol. 285 2003 E701 E707
28. M.K. Reimer, J.J. Holst, and B. Ahrén Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur. J. Endocrinol. 146 2002 717 727 (Pubitemid 34552507)
29. M.A. Sentandreu, and F. Toldrá Purification and biochemical properties of dipeptidyl peptidase I from porcine skeletal muscle J. Agric. Food Chem. 48 2000 5014 5022
30. G.P. Smith, R.R. MacGregor, and T.J. Peters Localization of leucine aminopeptidase and vitamin B-12 binding protein in rabbit peripheral blood polymorphonuclear leukocytes Biochim. Biophys. Acta 719 1982 532 538 (Pubitemid 13191715)
31. B. Sudre, P. Broqua, R.B. White, D. Ashworth, D.M. Evans, R. Haigh, J.L. Junien, and M.L. Aubert Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats Diabetes 51 2002 1461 1469 (Pubitemid 34826612)
32. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182 (Pubitemid 351439162)
33. C. Tourrel, D. Bailbe, M. Lacorne, M.J. Meile, M. Kergoat, and B. Portha Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 51 2002 1443 1452 (Pubitemid 34826610)
34. J.W. Williams, and J.F. Morrison The kinetics of reversible tight-binding inhibition Meth. Enzymol. 63 1979 437 467
35. B. Willms, J. Werner, J.J. Holst, C. Orskov, W. Creutzfeldt, and M.A. Nauck Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients J. Clin. Endocrinol. Metab. 81 1996 327 332